|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 358.33 USD | +1.56% |
|
+6.14% | +9.48% |
| Jun. 26 | US FDA greenlights Viridian's thyroid eye disease drug | RE |
| Jun. 26 | US FDA greenlights Viridian's eye disease drug | RE |
| Market Cap | 193B 170B 157B 147B 274B 18,253B 281B 1,881B 727B 9,011B 726B 710B 31,290B | P/E 2026 * |
23.3x | P/E 2027 * | 21.2x |
|---|---|---|---|---|---|
| Enterprise Value | 235B 206B 190B 178B 333B 22,145B 341B 2,282B 882B 10,932B 881B 862B 37,961B | EV / Sales 2026 * |
6.21x | EV / Sales 2027 * | 5.9x |
| Free-Float |
99.78% | Yield 2026 * |
2.81% | Yield 2027 * | 2.97% |
Last Transcript: Amgen Inc.
| 1 day | +1.56% | ||
| 1 week | +6.14% | ||
| Current month | +6.40% | ||
| 1 month | +6.63% | ||
| 3 months | +2.74% | ||
| 6 months | +7.63% | ||
| Current year | +9.48% |
| 1 week | 337.6 |  | 362.27 |
| 1 month | 322.3 | | 362.27 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.44 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
Esteban Santos
COO | Chief Operating Officer | 59 | 2016-07-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.56% | +6.14% | +29.30% | +60.97% | 193B | |
| +7.13% | +9.97% | +55.80% | +160.09% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +55.96% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.06% | 448B | |
| +0.99% | +4.85% | +28.17% | +23.89% | 332B | |
| +1.82% | +8.19% | +40.04% | +27.95% | 293B | |
| +0.22% | +6.75% | +31.30% | +42.34% | 286B | |
| +0.73% | +8.53% | -27.33% | -39.55% | 215B | |
| +3.26% | +3.33% | +15.55% | +68.24% | 159B | |
| +2.62% | -3.65% | +0.41% | -33.31% | 138B | |
| Average | +2.65% | +6.59% | +27.93% | +45.76% | 375.45B | |
| Weighted average by Cap. | +3.80% | +8.37% | +40.23% | +75.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.78B 33.19B 30.6B 28.63B 53.6B 3,566B 54.84B 367B 142B 1,760B 142B 139B 6,113B | 38.75B 34.04B 31.39B 29.36B 54.97B 3,657B 56.24B 377B 146B 1,805B 146B 142B 6,269B |
| Net income | 8.26B 7.26B 6.69B 6.26B 11.73B 780B 12B 80.38B 31.07B 385B 31.04B 30.35B 1,337B | 9.04B 7.94B 7.32B 6.85B 12.83B 853B 13.12B 87.92B 33.98B 421B 33.95B 33.2B 1,463B |
| Net Debt | 41.23B 36.22B 33.4B 31.24B 58.5B 3,892B 59.85B 401B 155B 1,921B 155B 151B 6,671B | 35.08B 30.82B 28.42B 26.58B 49.77B 3,311B 50.92B 341B 132B 1,635B 132B 129B 5,676B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-26 | $358.33 | +1.56% | 3,610,561 |
| 26-06-25 | $352.82 | +0.40% | 2,341,847 |
| 26-06-24 | $351.43 | +1.27% | 2,391,890 |
| 26-06-23 | $347.01 | +0.66% | 2,304,951 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
